Solu Therapeutics Lands $41M for Clinical Test of Novel Antibody Drug for Blood Cancer
Solu Therapeutics’ platform technology, which was licensed from GSK, pairs a small molecule with an antibody to address elusive disease targets. Cancer is Solu’s initial focus, but the startup is also exploring applications of its platform to immunology.